-+ 0.00%
-+ 0.00%
-+ 0.00%

Plus Therapeutics Provides A Business Update For Its Wholly-owned Subsidiary, CNSide Diagnostics, The CNSide Cerebrospinal Fluid Assay Platform Is Designed And Intended For Patients Suspected Of Having Central Nervous System Cancer Metastases

Benzinga·06/26/2025 11:35:06
Listen to the news
  • U.S. commercial rollout of novel diagnostic platform to begin second half 2025
  • Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion